



3 August 2012

## **ASX RELEASE**

### **ASX ANNOUNCEMENT – Strategic Realignment**

Brisbane, Australia - **ImpediMed Limited (ASX: IPD)** (the Company) announces today a strategic organisational realignment. This allows the business to focus on favourable reimbursement, accelerated adoption of our technology and disciplined execution.

This repositioning includes a headcount reduction from 42 to 29 employees and delays further expansion into Germany and Japan. These actions will better position ImpediMed to create value for our shareholders and improve the quality of life for our patients.

ImpediMed President & CEO, Mr. Richard Carreon said, “We deeply regret having to reduce our workforce. We thank those impacted for their significant contributions to IPD. This realignment dramatically streamlines our non-core business activities to improve the Company’s cost structure and focus on the core lymphoedema business.”

**Richard Carreon**  
**CEO**

## **ENDS**

**For further information contact:**

**Richard Carreon, ImpediMed CEO**  
**T: +1 (858) 412-0200**  
**M: +1 (619) 309-6230**

L-Dex<sup>®</sup> is a trademark of ImpediMed Limited.

The L-Dex scale is a tool to assist in the clinical assessment of unilateral lymphoedema of arm and leg in women and the leg in men by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity.

### **About ImpediMed**

ImpediMed Limited is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary unilateral lymphoedema of the arm and leg in women and the leg in men.

For more information, visit: [www.impedimed.com.au](http://www.impedimed.com.au)